Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,013 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, et al. · N Engl J Med · 2020Multicenter Study, Randomized Controlled Trial
- Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
Berg DD, Patel SM, Haller PM, et al. · Circulation · 2025Meta-Analysis, Randomized Controlled Trial
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV, Solomon SD, Inzucchi SE, et al. · N Engl J Med · 2019Clinical Trial, Phase III, Multicenter Study
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Claggett B, et al. · N Engl J Med · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
van Essen BJ, Ceelen DCH, Ouwerkerk W, et al. · J Am Coll Cardiol · 2025Systematic Review, Network Meta-Analysis
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA, Angermann CE, Teerlink JR, et al. · Nat Med · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
Vaduganathan M, Docherty KF, Claggett BL, et al. · Lancet · 2022Meta-Analysis
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Lancet · 2022Systematic Review, Meta-Analysis
- SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
Neuen BL, Fletcher RA, Anker SD, et al. · JAMA · 2026Meta-Analysis
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F, Ferreira JP, Pocock SJ, et al. · Lancet · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.
Carvalho PEP, Veiga TMA, Simões E Silva AC, et al. · Clin Res Cardiol · 2023Comparative Study, Meta-Analysis
- Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis.
Aldafas R, Crabtree T, Alkharaiji M, et al. · Age Ageing · 2024Meta-Analysis, Systematic Review
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME, Windsor SL, Borlaug BA, et al. · Nat Med · 2021Multicenter Study, Randomized Controlled Trial
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Nong K, Vandvik PO, et al. · BMJ · 2023Systematic Review, Network Meta-Analysis
- Diuretic Potentiation Strategies in Acute Heart Failure.
Siddiqi TJ, Packer M, Ezekowitz JA, et al. · JACC Heart Fail · 2025Systematic Review, Research Support, Non-U.S. Gov't
- Empagliflozin after Acute Myocardial Infarction.
Butler J, Jones WS, Udell JA, et al. · N Engl J Med · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
Usman MS, Bhatt DL, Hameed I, et al. · Lancet Diabetes Endocrinol · 2024Systematic Review, Meta-Analysis
- Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF.
Weintraub WS, Kolm P, Dolman S, et al. · JACC Heart Fail · 2024Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Vaduganathan M, Claggett BL, Jhund PS, et al. · Lancet · 2020Comparative Study, Randomized Controlled Trial
- Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.
Alghamdi M, Dihoum A, Hakami K, et al. · Diabetes Obes Metab · 2025Randomized Controlled Trial, Clinical Trial, Phase II
- Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Hamid AK, Tayem AA, Al-Aish ST, et al. · Ther Adv Cardiovasc Dis · 2024Systematic Review, Meta-Analysis
- Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
Bhatt AS, Bhatt DL, Steg PG, et al. · J Am Coll Cardiol · 2024Clinical Trial, Phase III, Multicenter Study
- Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis.
Ali AE, Mazroua MS, ElSaban M, et al. · Glob Heart · 2023Meta-Analysis, Systematic Review
- Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.
James S, Erlinge D, Storey RF, et al. · NEJM Evid · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
Banerjee M, Maisnam I, Pal R, et al. · Eur Heart J · 2023Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.